
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is projected to have a firm value of $33B, with an 8% discount rate and 2.0% terminal growth rate. Risks for the company include but are not limited to negative data for multiple of its programs, slower market uptake, potential delays in program advancement, partnership and M&A risks, regulatory risks, commercial risks, and possible long-term dilution risk.
Bears say
BioNTech is currently facing risks with its ROSETTA Lung-01 and Lung-02 trials as the recent Chinese data on pumitamig showed similar results to the global Phase 2 trial with an 82% confirmed ORR in 1L ES-SCLC and a 46.7% cORR in 1L NSCLC regardless of PD-L1 expression. Although these results are promising, they also raise concerns about the potential success of BioNTech's Phase 3 trials, which could affect the company's future revenue and profitability. Additionally, the company's heavy reliance on its Pfizer-partnered covid vaccine, Comirnaty, leaves it vulnerable to any potential setbacks or competition in the market, making it a risky investment option.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares